BMT CTN Protocol 1506

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.

Below are protocol-related documents, which may be periodically updated.

  • Protocol, Version 3.0 dated March 25, 2019
  • This study is posted on as NCT02997202
  • Key Personnel

             Protocol Co-Chair: Yi-Bin Chen, MD

             Protocol Co-Chair: Mark Levis, MD, PhD

             Protocol Officer: Mehdi Hamadani, MD        

             Protocol Coordinator: Heather Wittsack


The BMT CTN is committed to including widespread transplant community participation in these trials. For information on how to apply to participate on this study, please contact the Protocol Coordinator Heather Wittsack at for details.